

The Immune Response of Prolactin and the Induction of Tumor Necrosis Factor (TNF) in Iraqi Patients Infected with Hepatitis C Virus.


Prof. Hedef Dhafir El-Yassin (MRSC, Ph.D, Post Doctorate)

Department of Biochemistry, College of Medicine, University of Baghdad.


7/23/2016

Rana A. Hadi M.B.Ch. B. Candidate for the fellowship of the Iraqi Board for Medical Specialization in Pathology/ Clinical Chemistry



Prof. Dr. Hedef Dhafir El-Yassin 2016
Berlin/ Germany




- Viral Hepatitis Type C is a serious public health challenge throughout the world and remain to be the major causes of chronic hepatitis.
- During the 80s, Iraq had low endemicity among blood donors.
- However its prevalence is now increased with high rate of mortality.





- Hepatitis C is a contagious viral disease caused by hepatitis C virus.



- Brett D. Lindenbach and Charles M. Rice described a hypothesis for the detailed molecular mechanism of HCV infection in an article entitled :” The ins and outs of hepatitis C virus entry and assembly”, published in *Nature Reviews Microbiology* : Volume: 11, Pages:688–700 :(2013)




Prof. Dr. Hedef Dhafir
El-Yassin 2016 Berlin/
Germany 7/23/2016



(step 1)

- Hepatitis C virus (HCV) lipoviral particles (LVPs) attach to the cell surface by interacting with:
 - heparan sulphate proteoglycans (HSPGs),
 - low-density-lipoprotein receptor (LDLR) and
 - scavenger receptor class B member 1 (SRB1).
- SRB1 might delipidate HCV-associated lipoproteins and induces conformational changes in the E2 glycoprotein, exposing the CD81-binding site




(step 2)

- Interaction of E2 with CD81 then activates signal transduction through epidermal growth factor receptor (EGFR) and HRAS, as well as through RHO GTPases.

(step 3)

- These signaling events promote lateral movement of HCV– CD81 complexes to sites of cell–cell contact.




(step 4)


- Interaction of CD81 with claudin 1 (CLDN1), and HCV internalization via clathrin-mediated endocytosis.

(step 5)


- The low pH of the endosomal compartment induces HCV fusion.




- Many cases (two –third) could go through undiagnosed because they might be asymptomatic.
- However the rest one-third of people initially infected with hepatitis C develop symptoms and are more likely to be treatment efficiently with antiviral drugs.



Acute HCV Infection with Recovery




Source: Adapted from MMWR 1998; 47(No. RR19)




- Those infected but asymptomatic will develop to chronic HCV and will initiate a broad-based immune response. (adaptive and innate immune response).

Acute HCV Infection Evolving to Chronic Infection




Source: Adapted from MMWR 1998; 47(No. RR19)




Risk Factors Associated with Faster Fibrosis Progression in Chronic HCV


Prof. Dr. Helmut Dierfeldt
 El-Massi 2015 Berlin, Germany




Antivir Ther. 2010;15:281-91.
al. Lancet. 1997;349:825-32.



- It is clinically important
 1. to differentiate :
 - incident HCV infectionsfrom
 - chronic infections
 2. and to identify
 - primary infections that are asymptomatic.




- Occasional occurrences of acute exacerbation in chronic infection, will complicate decisions regarding whom to treat with the suitable treatment.(1)




Hepatitis C virus-related chronic hepatitis is associated with various immunological disorders example:

- Immuno-endocrine
- Cytokines
- Anti-tissue antibodies




- Interaction of these molecules might trigger a cascade of reaction that will be involved in the progression of the disease.
- And/or might influence the effect of drug of choice that is used for the management of the disease.






Aim of the study:

To evaluate the role of the immunoendocrine system in the pathogenesis of chronic hepatitis c, by measuring serum prolactin and tumor necrosis factor-alpha.




- Subjects involved in the study were selected from Gastrointestinal Hospital in Baghdad, Iraq .
- During the period from July 2014 to September 2014.
- A written consent was taken from each.






- All patients had chronic hepatitis C virus and were on interferon alpha therapy.
- All of them were positive for HCV RNA by means of polymerase chain reaction.




Diagnostic algorithm for hepatitis C




- Blood samples were collected between (9.00a.m-12.00p.m).
- The blood was allowed to clot in plain tube for 30-45 minutes at room temperature.
- Sera were obtained by centrifugation of the collected blood and then stored in plain tubes at -20 c.
- ELISA technique was used to measure (TNF and




Prolactin)



Parameter	Serum prolactin (ng/ml)			
Groups	Patients		Control s	
Mean \pm SEM	12.54	2.9	11.50	2.7




- The role of PRL in the immune reactions is stimulating; its presence significantly increases the ability of the immune cells to proliferate and produce cytokines such as TNF-alpha(2)




- Recent studies suggest that prolactin is important both for normal liver growth and for regenerating the liver after part of it is removed, with extra prolactin providing a boost for repair mechanisms. Consequently, enhancing prolactin levels could provide a way to improve regeneration when the liver becomes damaged or diseased with viruses, or after surgery.(3)


Parameter	Serum TNF-alpha (ng/ml)			
Groups	Patients		Controls	
Mean \pm SEM	65.57 $\times 10^{-3}$	7.03X 10^{-3}	41.52 $\times 10^{-3}$	1.86X 10^{-3}




- HCV infection enhances TNF- α -induced cell death by suppressing nuclear factor NF- κ B activation through the action of core, (non structural HCV) NS4B, and NS5B. This mechanism may contribute to immune-mediated liver injury in HCV infection. (4)



Correlation between serum prolactin and TNF in patients group





- The result agrees with Clifford et al in their study they reviewed the presence of autoimmune markers in sera of chronic hepatitis C patients.
- Their study showed that treatment with interferon alfa (IFN-alpha) will exacerbate autoimmune hepatitis. (5)
- The pathogenesis of autoimmune hepatitis due to medications is not clear.


Recommendations from an expert panel

- Aiming for treatment optimization by filling some of the gaps of the current guidelines, a group of Italian experts, experienced on treatment of HCV infection, met in Stresa in February 2016.
- The summary of all the considerations arising from this two-day meeting and the final statements are reported in *Digestive and Liver Disease Journal* June 2016 [Epub ahead of print]

- “Treatment of chronic HCV (CHC) has been revolutionized in the last few years by the introduction of highly effective and well tolerated direct acting antiviral agents (DAAs) able to achieve >90% rates of sustained virological response (SVR) in many groups of patients, including those previously excluded from interferon-based regimens.
- **For such reason interferon-free regimens are now the treatments of choice for all patients.**
- Successful anti-HCV treatment can stop liver disease progression and can solve the HCV-related extra hepatic manifestations, eventually reducing both liver-related and overall mortality.”


Conclusions:

- Chronic hepatitis C is associated with an immunological abnormality mainly represented by tumor necrosis factor-alpha and prolactine.
- This might shed a light of the type of therapy and drug of choice when managing the disease.



References:

1. C.H. Chen, and C.-S. Changchien. Is it possible to diagnose acute hepatitis C virus (HCV) infection by a rising anti-HCV titer rather than by seroconversion? *J. Viral Hepat.* 11:563–570, 2004
2. Fojtíková M¹, Cerná M, Pavelka K. A review of the effects of prolactin hormone and cytokine on the development and pathogenesis of autoimmune diseases. *Vnitr Lek.* 56(5):402-13, .2010 [Article in Czech].
3. CarmenC, Moreno B, Maite G. Prolactin promotes normal liver growth survival and regeneration in rodents. *American Physiological Society*; 10:1152, 2012.
4. Park J, Kang W, Ryu SW. Hepatitis C virus infection enhances TNF α -induced cell death via suppression of NF-Kb. *Journal of Hepatology*; 56(3):831-40, 2012
5. Clifford BD, Donahue D, Smith L. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. *Journal of Hepatology*; 21(3):613, 1995
6. Craxì A, Perno CF, Viganò M, Ceccherini-Silberstein F, Petta S; AdHoc (Advancing Hepatitis C for the Optimization of Cure) From current status to optimization of HCV treatment: Recommendations from an expert panel. *Dig Liver Dis.* 2016 Jun



Any questions?

Thank You